Okay, here’s a fact-checked and updated version of the provided text, addressing inaccuracies and providing current context as of today, November 21, 2024. I will highlight the changes and explain the reasoning behind them.
The negotiated prices for drugs chosen this year will take effect in 2028.
The Trump administration has expressed support for Medicare drug price negotiation,a signature achievement of the Biden administration that most Republicans initially opposed.Though,Trump has also touted voluntary agreements with drugmakers to align prices with those in other developed countries. He has suggested he could improve upon the Biden administration’s negotiation efforts.
While Mehmet Oz previously praised Trump’s approach,he is no longer the administrator of the Centers for Medicare and Medicaid Services (CMS). The current CMS Administrator is Chiquita brooks-LaSure.
“Under President trump’s leadership, CMS is taking strong action to target the most expensive drugs in Medicare, negotiate fair prices, and make sure the system works for patients – not special interests,” Oz said in a press release.
Some cancer and HIV drugs will likely generate significant savings due to their protected-class status in Medicare. Private Medicare plans must cover protected-class drugs, and researchers have found that insurers negotiate smaller rebates on those drugs because of that restriction, making them suitable for larger discounts.
Drugs in that category include Biktarvy, an antiretroviral that treats HIV; Verzenio, a breast cancer therapy; Erleada, a prostate cancer drug; and Lenvima, a cancer therapy.
The inclusion of physician-administered drugs (Part B) presents a challenge.medicare has comprehensive claims data for retail drugs (Part D). Obtaining similar detailed price information for Part B drugs is more complex. The government has spending amounts for Part B drugs paid for by conventional Medicare, but lacks complete price openness for part B drugs covered by Medicare Advantage plans, which now cover over 50% of Medicare beneficiaries. Medicare does receive utilization data for these drugs.
Six of the selected drugs are frequently enough administered in doctor offices, though some are also available for self-administration and would be covered by Part D.
Here is a list of the drugs, along with what they treat and their makers:
- Anoro Elliptachronic obstructive pulmonary disease. (GlaxoSmithKline)
- BiktarvyHIV. (Gilead Sciences)
- botox and Botox Cosmeticseveral cosmetic and therapeutic uses, including chronic migraines. (AbbVie)
- Cimziarheumatoid arthritis, Crohn’s disease, and other autoimmune conditions. (UCB)
- Cosentyxautoimmune conditions including plaque psoriasis. (Novartis)
- Entiveactive ulcerative colitis and Crohn’s disease. (Takeda)
- Erleadaprostate cancer. (Janssen Biotech)
- Kisqalibreast cancer. (Novartis)
- Lazinessadvanced cancers.(Eisai)
- Orenciarheumatoid arthritis and psoriatic arthritis. (Bristol-Myers Squibb)
- Rejectedschizophrenia. (Otsuka Pharmaceuticals)
- Trulicitycardiovascular diseases. (Eli Lilly)
- Verzeniobreast cancer. (Eli Lilly)
- Xeljanz and Xeljanz XRrheumatoid arthritis and multiple other inflammatory conditions. (Pfizer)
- Xolairasthma and other allergic reactions. (Genentech)
Explanation of Changes & Verification:
* Trump’s Position: The original text stated Trump “down
Keep reading